百利天恒(02615)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02615 百利天恒

待上市 07-06 16:00:00

0.000

+0.000

--

最高0.000	最低0.000	成交量0.00
今开0.000	昨收0.000	日振幅0.00%
总市值0.00	流通市值0.00	总股本4.22亿
成交额0.00	换手率0.00%	流通股本4.22亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02615","market":"HK","secType":"STK","nameCN":"百利天恒","latestPrice":0,"timestamp":1783324800000,"preClose":0,"halted":7,"volume":0,"delay":0,"floatShares":421508117,"shares":421508117,"eps":0,"marketStatus":"待上市","change":0,"latestTime":"07-06 16:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.204,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":4102450200000},"marketStatusCode":8,"adr":0,"listingDate":4102416000000,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1783301400000,1783310400000],[1783314000000,1783324800000]],"volumeRatio":0,"ipoDetail":{"name":"百利天恒","exchange":"SEHK","listingDate":"2100-01-01","sharesOutstanding":421508117,"sharesFloat":421508117,"offerAmount":8634300,"priceRange":"347.500 - 389.000","market":"HK","openProspectusDate":"2025-11-07","openProspectusUrl":"https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1107/2025110700014_c.pdf","purchaseBeginDate":"2025-11-07","purchaseEndDate":"2025-11-12","winningDate":"2025-11-14","currency":"HKD","minPurchaseQuantity":100,"peRate":39.25,"use":"1、约60.0%或1,810.5百万港元将用于拨付于中国内地以外地区的生物候选药物的研发活动；\n2、约30.0%或905.2百万港元将用于建立全球供应链，主要为在中国内地以外地区的生物候选药物的新生产设施的建设或潜在收购机会提供资金；\n3、约10.0%或301.7百万港元将用于拨付在中国内地以外业务的营运资金及其他一般公司用途。","industryId":"204005","industryName":"医疗保健","business":"公司是一家具备早期研发、临床开发、生产及商业化能力的综合医疗企业集团。","subscribed":19.93,"marketCap":146474000000,"minimumCapital":39292.31,"overAllotment":false,"lotSize":100,"issueOpenRate":0.1,"subscribeGear":"100,200,300,400,500,600,700,800,900,1000,1500,2000,2500,3000,3500,4000,4500,5000,6000,7000,8000,9000,10000,15000,20000,25000,30000,35000,40000,45000,50000,60000,70000,80000,90000,100000,150000,200000,300000,431700"},"greyMarketDetail":{"greyDate":"2099-12-31","greyDateTimestamp":4102329600000,"greyOpeningTime":4102388100000,"greyClosingTime":4102396200000,"showGreyQuote":false,"openProspectusDate":"2025-11-07","listingDate":"2100-01-01"},"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688506","market":"SH","secType":"STK","nameCN":"百利天恒","latestPrice":330,"timestamp":1783321200000,"preClose":340,"halted":0,"volume":4293500,"delay":0,"premium":"-100.00"}},"requestUrl":"/m/hq/s/02615","defaultTab":"news","newsList":[{"id":"2648683010","title":"百利天恒（688506）披露股份回购进展公告，7月2日股价上涨4.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648683010","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648683010?lang=zh_cn&edition=full","pubTime":"2026-07-02 22:07","pubTimestamp":1783001235,"startTime":"0","endTime":"0","summary":"截至2026年7月2日收盘，百利天恒报收于335.5元，较前一交易日上涨4.88%，最新总市值为1385.19亿元。该股当日开盘310.95元，最高353.88元，最低310.01元，成交额达17.43亿元，换手率为1.28%。近日，四川百利天恒药业股份有限公司发布《关于股份回购进展公告》。公告显示，公司于2026年6月1日召开董事会，审议通过以集中竞价交易方式回购股份的方案，回购期限为2026年6月1日至2027年5月31日，拟回购金额为10,000万元至20,000万元，回购价格不超过398元/股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200041804.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02615","91194","BK0239","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647322872","title":"6月29日百利天恒涨13.11%，中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647322872","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647322872?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:40","pubTimestamp":1782722430,"startTime":"0","endTime":"0","summary":"证券之星消息，6月29日百利天恒涨13.11%，收盘报297.01元，换手率1.01%，成交量4.16万手，成交额11.93亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共128家，其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。中欧医疗健康混合A目前规模为129.74亿元，最新净值1.703，较上一交易日下跌1.34%，近一年上涨2.14%。中欧医疗健康混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024490.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","159760","02615","91194","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647322393","title":"百利天恒涨13.11%，开源证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2647322393","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647322393?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:40","pubTimestamp":1782722424,"startTime":"0","endTime":"0","summary":"今日百利天恒涨13.11%，收盘报297.01元。2026年4月29日，开源证券研究员余汝意,聂媛媛发布了对百利天恒的研报《Iza-bren商业化在即，多产品将开展全球注册临床》，该研报对百利天恒给出“买入”评级。研报中预计公司2026-2028年营收为24.76/22.99/30.76，当前股价对应PE分别为47.5/51.5/38.2倍，维持“买入”评级。此外，山西证券研究员邓周宇,魏赟,张智勇，东吴证券研究员朱国广近期也对该股发布了研报，同样给出“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024485.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02615","688506","91194","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646149353","title":"百利天恒：证券事务代表陈雪玉辞任","url":"https://stock-news.laohu8.com/highlight/detail?id=2646149353","media":"南方财经网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646149353?lang=zh_cn&edition=full","pubTime":"2026-06-26 17:19","pubTimestamp":1782465540,"startTime":"0","endTime":"0","summary":"南财智讯6月26日电，百利天恒公告，公司董事会近日收到证券事务代表陈雪玉女士递交的辞职报告，因个人原因，陈雪玉女士申请辞去公司证券事务代表、证券事务部总监职务，辞职后不再担任公司任何职务。其辞职报告自送达公司董事会之日起生效，不会对公司正常经营活动产生不利影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606263784845032.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["91194","161027","688506","BK0239","02615"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646984873","title":"6月25日百利天恒涨10.21%，中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2646984873","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646984873?lang=zh_cn&edition=full","pubTime":"2026-06-25 16:36","pubTimestamp":1782376614,"startTime":"0","endTime":"0","summary":"证券之星消息，6月25日百利天恒涨10.21%，收盘报273.0元，换手率0.85%，成交量3.49万手，成交额9.09亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共128家，其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。中欧医疗健康混合A目前规模为129.74亿元，最新净值1.6918，较上一交易日上涨3.89%，近一年上涨0.44%。中欧医疗健康混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500029628.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","688506","159760","02615","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646873985","title":"百利天恒涨10.21%，开源证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2646873985","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646873985?lang=zh_cn&edition=full","pubTime":"2026-06-25 16:36","pubTimestamp":1782376602,"startTime":"0","endTime":"0","summary":"今日百利天恒涨10.21%，收盘报273.0元。2026年4月29日，开源证券研究员余汝意,聂媛媛发布了对百利天恒的研报《Iza-bren商业化在即，多产品将开展全球注册临床》，该研报对百利天恒给出“买入”评级。研报中预计公司2026-2028年营收为24.76/22.99/30.76，当前股价对应PE分别为47.5/51.5/38.2倍，维持“买入”评级。此外，山西证券研究员邓周宇,魏赟,张智勇，东吴证券研究员朱国广近期也对该股发布了研报，同样给出“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500029623.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","02615","91194","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645881028","title":"6月23日百利天恒涨10.97%，中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645881028","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645881028?lang=zh_cn&edition=full","pubTime":"2026-06-23 16:52","pubTimestamp":1782204743,"startTime":"0","endTime":"0","summary":"证券之星消息，6月23日百利天恒涨10.97%，收盘报252.43元，换手率1.15%，成交量4.75万手，成交额11.66亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共128家，其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。中欧医疗健康混合A目前规模为129.74亿元，最新净值1.5972，较上一交易日上涨1.42%，近一年下跌3.16%。中欧医疗健康混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300028448.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159760","02615","91194","688506","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645093881","title":"百利天恒涨10.97%，开源证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2645093881","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645093881?lang=zh_cn&edition=full","pubTime":"2026-06-23 16:52","pubTimestamp":1782204734,"startTime":"0","endTime":"0","summary":"今日百利天恒涨10.97%，收盘报252.43元。2026年4月29日，开源证券研究员余汝意,聂媛媛发布了对百利天恒的研报《Iza-bren商业化在即，多产品将开展全球注册临床》，该研报对百利天恒给出“买入”评级。研报中预计公司2026-2028年营收为24.76/22.99/30.76，当前股价对应PE分别为47.5/51.5/38.2倍，维持“买入”评级。此外，山西证券研究员邓周宇,魏赟,张智勇，东吴证券研究员朱国广近期也对该股发布了研报，同样给出“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300028445.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","02615","91194","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645294190","title":"全球首个获批双抗ADC上市，百利天恒(688506.SH)加速向MNC跨代跃迁","url":"https://stock-news.laohu8.com/highlight/detail?id=2645294190","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645294190?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:01","pubTimestamp":1782126096,"startTime":"0","endTime":"0","summary":"作为全球首创EGFR×HER3双抗ADC，百利天恒的1类新药宜泽康在国内获批上市，用于复发/转移性鼻咽癌后线治疗。6月22日，百利天恒发布的这则重磅公告，引发了市场的广泛关注。本次获批，也标志着肿瘤治疗正式迈入双抗ADC新时代。此次在国内获批上市，是宜泽康加速成为“下一代基石癌症疗法”的第一步。该药由此成为全球第二款迈入III期临床开发的DLL3 ADC药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457060.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02615","91194","IPOS","BK4080","688506","BK0239","ADC","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643466202","title":"百利天恒最新公告：EGFR×HER3双抗ADC治疗三阴乳腺癌上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2643466202","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643466202?lang=zh_cn&edition=full","pubTime":"2026-06-14 16:20","pubTimestamp":1781425238,"startTime":"0","endTime":"0","summary":"百利天恒(688506.SH)公告称，公司自主研发的全球首创EGFR×HER3双抗ADC(iza-bren)用于治疗局部晚期或转移性三阴乳腺癌的药品上市申请已获国家药监局药审中心受理。该申请基于III期临床试验期中分析结果，该试验达到无进展生存期和总生存期双主要终点，为全球首个双抗ADC在三阴乳腺癌中取得双阳性结果的III期研究。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061400003053.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","91194","688506","02615"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643582246","title":"百利天恒最新公告：注射用BL-M14D1（DLL3ADC）联合用药治疗广泛期小细胞肺癌药物临床试验获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2643582246","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643582246?lang=zh_cn&edition=full","pubTime":"2026-06-14 16:00","pubTimestamp":1781424002,"startTime":"0","endTime":"0","summary":"百利天恒(688506.SH)公告称，公司近日收到国家药品监督管理局(NMPA)正式批准签发的《药物临床试验批准通知书》，公司自主研发的创新生物药BL-M14D1（DLL3 ADC）的联合用药的临床试验获得批准，同意该药品开展联合PD-1/PD-L1单抗±抗血管生成药物±化疗治疗广泛期小细胞肺癌的临床试验。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061400002006.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02615","688506","BK0239","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642110265","title":"百利天恒涨6.24%，开源证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2642110265","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642110265?lang=zh_cn&edition=full","pubTime":"2026-06-12 16:30","pubTimestamp":1781253002,"startTime":"0","endTime":"0","summary":"今日百利天恒涨6.24%，收盘报232.0元。2026年4月29日，开源证券研究员余汝意,聂媛媛发布了对百利天恒的研报《Iza-bren商业化在即，多产品将开展全球注册临床》，该研报对百利天恒给出“买入”评级。研报中预计公司2026-2028年营收为24.76/22.99/30.76，当前股价对应PE分别为47.5/51.5/38.2倍，维持“买入”评级。此外，山西证券研究员邓周宇,魏赟,张智勇，东吴证券研究员朱国广近期也对该股发布了研报，同样给出“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061200025400.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02615","91194","688506","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642820662","title":"百利天恒：60亿元科技创新债券注册获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2642820662","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642820662?lang=zh_cn&edition=full","pubTime":"2026-06-11 20:58","pubTimestamp":1781182680,"startTime":"0","endTime":"0","summary":"6月11日，百利天恒（688506）发布公告，公司收到中国银行间市场交易商协会出具的《接受注册通知书》，决定接受公司科技创新债券注册。本次注册的基础品种为中期票据，注册金额为60亿元，注册额度自《接受注册通知书》落款之日起2年内有效，在注册有效期内，公司可分期发行科技创新债券，并将根据市场情况适时安排中期票据的发行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606113768540761.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688506","BK0239","02615","BNDW","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642449086","title":"6月10日百利天恒涨5.30%，中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642449086","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642449086?lang=zh_cn&edition=full","pubTime":"2026-06-10 16:40","pubTimestamp":1781080815,"startTime":"0","endTime":"0","summary":"证券之星消息，6月10日百利天恒涨5.30%，收盘报219.98元，换手率0.67%，成交量2.78万手，成交额6.03亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共128家，其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。中欧医疗健康混合A目前规模为129.74亿元，最新净值1.5035，较上一交易日上涨0.53%，近一年下跌14.06%。中欧医疗健康混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061000029349.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02615","159760","BK0239","688506","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642246107","title":"山西证券：给予百利天恒买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2642246107","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642246107?lang=zh_cn&edition=full","pubTime":"2026-06-09 18:43","pubTimestamp":1781001805,"startTime":"0","endTime":"0","summary":"山西证券股份有限公司邓周宇,魏赟,张智勇近期对百利天恒进行研究并发布了研究报告《EGFR×HER3双抗ADC iza-bren硕果频出，多管线驱动成长》，给予百利天恒买入评级。iza-bren后线鼻咽癌、后线食管鳞癌NDA受理并纳入优先审评；三阴性乳腺癌III期达主要终点，计划提交NDA。持续覆盖，给予“买入-B”评级。最新盈利预测明细如下：该股最近90天内共有4家机构给出评级，买入评级4家；过去90天内机构目标均价为361.02。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060900030326.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02615","688506","91194","002500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641045171","title":"百利天恒(688506.SH)：BL-M14D1(DLL3ADC)联合免疫治疗用于一线广泛期小细胞肺癌患者的III期临床试验申请获得FDA许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2641045171","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641045171?lang=zh_cn&edition=full","pubTime":"2026-06-08 15:36","pubTimestamp":1780904174,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒 发布公告，公司的全资子公司 SystImmune,Inc.近日收到美国食品药品监督管理局的通知， BL-M14D1联合免疫治疗用于一线广泛期小细胞肺癌患者的III期临床试验申请已获得FDA许可。BL-M14D1与iza-bren 共享同一小分子技术平台，公司拥有其完整的全球权益。本次BL-M14D1的III期临床研究获得FDA的IND许可，将进一步推进公司业务和产品国际化布局的进程，对公司近期业绩不会产生重大影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451325.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02615","91194","688506","BK4585","BL","LABU","BK0239","BK4134","BK4023","LU0757428866.USD","LU1815336091.USD","III","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641812784","title":"每周股票复盘：百利天恒（688506）拟回购1亿至2亿元股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2641812784","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641812784?lang=zh_cn&edition=full","pubTime":"2026-06-07 01:55","pubTimestamp":1780768512,"startTime":"0","endTime":"0","summary":"截至2026年6月5日收盘，百利天恒报收于212.29元，较上周的238.57元下跌11.02%。本周，百利天恒6月1日盘中最高价报243.9元。本周关注点公司公告汇总：百利天恒拟以集中竞价交易方式回购股份，金额不低于10,000万元且不超过20,000万元。公司公告汇总四川百利天恒药业股份有限公司于2026年6月1日召开第五届董事会第八次会议，审议通过《关于以集中竞价交易方式回购公司股份方案的议案》。董事会已授权公司管理层办理本次回购相关事宜。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060700000479.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02615","688506","BK0239","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640197152","title":"依托成熟毒素平台 百利天恒BL-M05D1胃癌III期试验完成首例入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2640197152","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640197152?lang=zh_cn&edition=full","pubTime":"2026-06-04 19:52","pubTimestamp":1780573920,"startTime":"0","endTime":"0","summary":"6月4日，百利天恒（688506）发布公告，公司自主研发的创新生物药注射用BL-M05D1（Claudin18.2ADC）用于在既往经一线治疗的Claudin18.2阳性晚期胃癌或胃食管结合部腺癌的III期临床试验已完成首例受试者入组。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606043760581427.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688506","BL","BK0239","III","LU0757428866.USD","02615","BK4134","LU1815336091.USD","BK4023","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640154692","title":"百利天恒：注射用BL-M08D1获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2640154692","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640154692?lang=zh_cn&edition=full","pubTime":"2026-06-04 18:54","pubTimestamp":1780570440,"startTime":"0","endTime":"0","summary":"南财智讯6月4日电，百利天恒公告，百利天恒（简称）收到国家药品监督管理局正式批准签发的《药物临床试验批准通知书》。公司自主研发的创新生物药注射用BL-M08D1（ADC）联合用药的临床试验获得批准，适应症为弥漫大B细胞淋巴瘤。该药物与iza-bren出自同一技术平台，共享同一“连接子+毒素”平台。公司将按规定积极推进研发项目，并及时履行后续信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606043760550358.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK4023","LU0757428866.USD","BL","02615","91194","688506","LU1815336091.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640115566","title":"公募FOF年内新发规模超千亿元；谢治宇、葛兰调仓百利天恒","url":"https://stock-news.laohu8.com/highlight/detail?id=2640115566","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640115566?lang=zh_cn&edition=full","pubTime":"2026-06-04 17:02","pubTimestamp":1780563760,"startTime":"0","endTime":"0","summary":"天赐良基日报第889期一、今日基金新闻速览1、公募FOF年内新发规模超千亿元公开数据显示，按认购起始日计算，截至6月3日，今年以来新发FOF产品91只，其中80只产品（份额合并计算）已经结募并公布认购情况，有效认购金额合计达到1049.07亿元。2、科技主题基金业绩现分化Wind数据显示，截至6月1日，名字中带“科技”的主动权益类基金中，今年以来回报率最高的基金业绩接近80%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606043760472889.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606043760472889.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["91194","BK0239","02615","688506","FOF"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.baili-pharm.com","compareEarnings":[{"period":"1week","weight":0.0299},{"period":"1month","weight":-0.0891},{"period":"3month","weight":-0.0703},{"period":"6month","weight":-0.1135},{"period":"1year","weight":-0.0299},{"period":"ytd","weight":-0.089}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"公司是一家聚焦于全球生物医药前沿领域，立足于解决临床未被满足的需求，具备包括小分子化学药、大分子生物药及ADC药物的全系列药品研究开发能力，并拥有从中间体、原料药到制剂一体化优势的、覆盖“研发—生产—营销”完整全生命周期商业化运营能力的生物医药企业。公司拥有两大业务板块,分别为创新生物药业务和化药制剂、中成药制剂业务板块。公司主要产品:丙泊酚乳状注射液、丙泊酚中/长链脂肪乳注射液、吸入用七氟烷、结构脂肪乳注射液(C6~24)、黄芪颗粒、盐酸胍法辛缓释片、葡萄糖电解质泡腾片。","exchange":"SEHK","name":"百利天恒","nameEN":"BIOKIN"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百利天恒(02615)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百利天恒(02615)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百利天恒,02615,百利天恒股票,百利天恒股票老虎,百利天恒股票老虎国际,百利天恒行情,百利天恒股票行情,百利天恒股价,百利天恒股市,百利天恒股票价格,百利天恒股票交易,百利天恒股票购买,百利天恒股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百利天恒(02615)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百利天恒(02615)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}